CTKB | Cytek biosciences inc - Stock Value & PE Ratio Analysis

3

24

15

Limited Growth

AI analysis rates CTKB with a lower value score of 2.
It is mainly due to unstable operating cash flow, along with potential value may be lower.
Over the past 3 months, CTKB has maintained an average value rating of 1.8, slightly higher than the rating of 0.5 over the past 3 years. However, growth opportunities for enterprise value remain relatively low.
Compared to all stocks in the Health Care sector, CTKB has a medium value rating.

CTKB Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/03/07 (Weekly Update)

CTKB Financial Forecast

Unit : USD

Update to 2025/5/16 (Quarterly Update)

CTKB Earnings Table

Unit : USD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	0.07	0%	40%	33.65M	-42.2%	-43.3%	1.8%
2024Q2	0.01	0%	166.7%	51.5M	7.3%	-15.4%	-22.4%
2024Q1	-0.08	-900%	166.7%	46.62M	-6.2%	-8.1%	-13.8%
2023Q4	-0.05	-66.7%	0%	44.86M	21%	2.9%	9.5%
2023Q3	0.07	0%	133.3%	58.23M	20.5%	2.9%	-13.5%

Update to 2025/5/16 (Quarterly Update)

CTKB Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

CTKB Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of CTKB from 2021/09 till Now

-
Cumulative Return: -
Annual Return: -
Volatility: -
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from September, 2021 to May, 2025. (Total Trades: 0)